Premium
Pharmacokinetics and bioavailability of erythromycin in pigeons ( Columba livia )
Author(s) -
VANHAECKE E.,
BACKER P.,
REMON J. P.,
DEVRIESE L. A.
Publication year - 1990
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/j.1365-2885.1990.tb00789.x
Subject(s) - bioavailability , erythromycin , pharmacokinetics , pharmacology , cmax , oral administration , chemistry , thiocyanate , antibiotics , medicine , biochemistry
Vanhaecke, E., De Backer, P., Remon, J.P. & Devriese, L.A. Pharmacokinetics and bioavailability of erythromycin in pigeons ( Columba livia ). J. vet. Pharmacol. Therap. 13, 356–360. Tissue and plasma concentrations were determined after intravenous and oral administration of erythromycin to pigeons to establish the pharmacokinetics and bioavailability of the drug. A short mean half‐life of elimination of 0.9 h was found. The relative bioavailability after direct crop administration of erythromycin thiocyanate or erythromycin ethylsuccinate at a dosage rate of 100 mg/kg was less than 10%. At a drug concentration in drinking water of I g/I, erythromycin plasma levels were barely detectable, whilst lung and trachea concentrations reached a maximum of 1.6 μg/ml. Even after crop administration of 100‐mg/kg erythromycin thiocyanate, low plasma levels were obtained, whilst lung and trachea concentrations were substantially higher. Prescribed drinking‐water regimens seemed unable to yield therapeutic tissue concentrations. Only individual crop administration seemed an appropriate medication method. The use of erythromycin ethylsuccinate did not present any advantage in comparison with erythromycin thiocyanate. J. P. Remon, Laboratory of Pharmaceutical Technology, Slate University of Ghent, Harelbekestraat 72, B‐9000 Ghent, Belgium.